section name header

Pronunciation

a-seet-oh-hye-drox-AM-ik A-sid

Classifications

Therapeutic Classification: anti-infectives (adjunct)

Pharmacologic Classification: urease inhibitors

Indications

REMS


Action

  • Reversibly inhibits the bacterial enzyme urease, which results in decreased hydrolysis of urea and subsequent production of ammonia in urine infected with urea-splitting bacteria.
Therapeutic effects:
  • Decreased urinary ammonia levels and decreased urine pH, which increases the efficacy of anti-infective therapy and cure rates.
  • Does not directly alter pH or have any direct antibacterial activity.

Pharmacokinetics

Absorption: Well absorbed following oral administration.

Distribution: Distributed throughout body water.

Metabolism/Excretion: 36–65% excreted unchanged in urine.

Half-Life: 5–10 hr (increased in renal impairment).

Time/Action Profile

(effect on urine)

ROUTEONSETPEAKDURATION
PO4–8 hrs0.25–1 hr6–8 hr



Blood levels.

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: palpitations, superficial phlebitis of the lower extremities

Derm: alopecia, rash (in association with alcohol)

GI: anorexia,, nausea,, vomiting

Hemat: anemia, hemolytic anemia

Neuro: anxiety, depression, headache, malaise, nervousness, tremulousness

Interactions

Drug-drug:

Route/Dosage

Renal Impairment

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

AHA, Lithostat

Code

NDC Code